A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic lymphocytic leukemia (CLL). Pipeline therapies discussed include BTK inhibitor + BCL2 inhibitor + CD20 mAb triplet regimens, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy. 

This interview was conducted on 22 May 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.